Glycogen Synthase Kinase 3 (GSK3) inhibitor - Pipeline Insight, 2022
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Glycogen Synthase Kinase 3 (GSK3) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Glycogen Synthase Kinase 3 (GSK3) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Overview
Glycogen synthase kinase 3 (GSK3) is a protein kinase that phosphorylated and inhibited glycogen synthase, the enzyme that catalyzes the transfer of glucose from UDPG to glycogen. Glycogen-synthase kinase-3 (GSK3) exists in two isoforms, termed ? and ?, which are generated from distinct genes. GSK3 is active in its basal state and is inhibited upon phosphorylation at Ser9 in GSK-3? and at Ser21 in GSK3?. GSK3 is a multifunctional protein kinase and has a broad range of substrates including signaling and structural proteins, as well as transcription factors. It is involved in various key biological processes, including glucose regulation, apoptosis, protein synthesis, cell signaling, cellular transport, gene transcription, proliferation, and intracellular communication. Accordingly, GSK-3 has been implicated in a wide variety of diseases and therefore specifically targeted for both therapeutic and imaging applications.
Report Highlights
This segment of the Glycogen Synthase Kinase 3 (GSK3) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Emerging Drugs
Further product details are provided in the report……..
Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glycogen Synthase Kinase 3 (GSK3) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs.
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Glycogen Synthase Kinase 3 (GSK3) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Glycogen Synthase Kinase 3 (GSK3) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Overview
Glycogen synthase kinase 3 (GSK3) is a protein kinase that phosphorylated and inhibited glycogen synthase, the enzyme that catalyzes the transfer of glucose from UDPG to glycogen. Glycogen-synthase kinase-3 (GSK3) exists in two isoforms, termed ? and ?, which are generated from distinct genes. GSK3 is active in its basal state and is inhibited upon phosphorylation at Ser9 in GSK-3? and at Ser21 in GSK3?. GSK3 is a multifunctional protein kinase and has a broad range of substrates including signaling and structural proteins, as well as transcription factors. It is involved in various key biological processes, including glucose regulation, apoptosis, protein synthesis, cell signaling, cellular transport, gene transcription, proliferation, and intracellular communication. Accordingly, GSK-3 has been implicated in a wide variety of diseases and therefore specifically targeted for both therapeutic and imaging applications.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Glycogen Synthase Kinase 3 (GSK3) Inhibitor R&D. The therapies under development are focused on novel approaches for Glycogen Synthase Kinase 3 (GSK3) Inhibitor.
This segment of the Glycogen Synthase Kinase 3 (GSK3) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Emerging Drugs
- Tideglusib: AMO Pharma
- 9 ING 41: Actuate Therapeutics
Further product details are provided in the report……..
Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Glycogen Synthase Kinase 3 (GSK3) Inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glycogen Synthase Kinase 3 (GSK3) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs.
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Report Insights
- Glycogen Synthase Kinase 3 (GSK3) Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs?
- How many Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Glycogen Synthase Kinase 3 (GSK3) Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glycogen Synthase Kinase 3 (GSK3) Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Glycogen Synthase Kinase 3 (GSK3) Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- AMO Pharma
- Actuate Therapeutics
- Rock Creek Pharmaceuticals
- BCN Biosciences
- HitGen
- Tideglusib
- 9 ING 41
- Anatabine
- BCN-057
- Research program: glycogen synthase kinase 3 beta inhibitors
Introduction
Executive Summary
Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Glycogen Synthase Kinase 3 (GSK3) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Glycogen Synthase Kinase 3 (GSK3) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tideglusib: AMO Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
9 ING 41: ACTUATE THERAPEUTICS
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BCN-057 BCN Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Key Companies
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Key Products
Glycogen Synthase Kinase 3 (GSK3) Inhibitor- Unmet Needs
Glycogen Synthase Kinase 3 (GSK3) Inhibitor- Market Drivers and Barriers
Glycogen Synthase Kinase 3 (GSK3) Inhibitor- Future Perspectives and Conclusion
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Analyst Views
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Key Companies
Appendix
Executive Summary
Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Glycogen Synthase Kinase 3 (GSK3) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Glycogen Synthase Kinase 3 (GSK3) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tideglusib: AMO Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
9 ING 41: ACTUATE THERAPEUTICS
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BCN-057 BCN Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Key Companies
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Key Products
Glycogen Synthase Kinase 3 (GSK3) Inhibitor- Unmet Needs
Glycogen Synthase Kinase 3 (GSK3) Inhibitor- Market Drivers and Barriers
Glycogen Synthase Kinase 3 (GSK3) Inhibitor- Future Perspectives and Conclusion
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Analyst Views
Glycogen Synthase Kinase 3 (GSK3) Inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Glycogen Synthase Kinase 3 (GSK3) Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Glycogen Synthase Kinase 3 (GSK3) Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Glycogen Synthase Kinase 3 (GSK3) Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Glycogen Synthase Kinase 3 (GSK3) Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
